---
title: "Zhongheng Group's wholly-owned subsidiary has received the approval notice for drug clinical trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236023083.md"
description: "Zhongheng Group's wholly-owned subsidiary, Guangxi Zhongheng Innovative Pharmaceutical Research Co., Ltd., has received the clinical trial notification for Sanqi Granules approved by the National Medical Products Administration. This drug will be used for Phase II and III clinical trials for chronic glomerulonephritis, meeting the drug registration requirements"
datetime: "2025-04-15T10:17:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236023083.md)
  - [en](https://longbridge.com/en/news/236023083.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236023083.md)
---

# Zhongheng Group's wholly-owned subsidiary has received the approval notice for drug clinical trials

According to the announcement from Zhongheng Group (600252.SH), on April 14, 2025, the company's wholly-owned subsidiary Guangxi Zhongheng Innovative Pharmaceutical Research Co., Ltd. (referred to as "Zhongheng Innovation") received the Clinical Trial Approval Notice for Sanqi Granules (Specification: 5g per bag) issued by the National Medical Products Administration. According to the Drug Administration Law of the People's Republic of China and relevant regulations, after review, the Sanqi Granules accepted on January 14, 2025, meet the relevant requirements for drug registration, and approval is granted to sequentially conduct Phase II and III clinical trials for chronic glomerulonephritis

### Related Stocks

- [600252.CN](https://longbridge.com/en/quote/600252.CN.md)

## Related News & Research

- [Shanghai Industrial Expands into HK Student Housing with Connected Lease Deal](https://longbridge.com/en/news/287207683.md)
- [OIL TANKERS AND CONTAINER SHIPS INCLUDED IN LAST 24 HOURS: TV.](https://longbridge.com/en/news/287242964.md)
- [Lycra Company Says To Successfully Complete Comprehensive Financial Restructuring](https://longbridge.com/en/news/286992700.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [RITFIT Partners with LA Galaxy's Marco Reus, Redefining High Quality Training at Home and Showcasing the Evolution of Professional Home Gym Ecosystems](https://longbridge.com/en/news/287232960.md)